Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994-2004

Diabetes Care

Volumn 30, Issue 4, 2007, Pages 848-853

  Rathmann, Wolfgang ^a,b   Haastert, Burkhard ^a   Icks, Andrea ^a   Giani, Guido ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLINIDE DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOSIDASE INHIBITOR; GLYCOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRATE; SULFONYLUREA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; FEMALE; GERMANY; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; OUTPATIENT DEPARTMENT; PRESCRIPTION; PREVALENCE;

COSTS AND COST ANALYSIS; DIABETES MELLITUS; FEMALE; GERMANY; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PRESCRIPTIONS, DRUG;

EID: 34147165663     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2000     Document Type: Article

References (21)

1. Grant RW, Pirraglia PA, Meigs JB, Singer DE: Trends in the complexity of diabetes care in the United States from 1991 to 2000. Arch Intern Med 164:1134-1139, 2004
2. Cohen FJ, Neslusan CA, Conklin JE, Song X: Recent antihyperglycemic prescribing trends for U.S. privately insured patients with type 2 diabetes. Diabetes Care 26:1847-1851, 2003
3. Wysowski DK, Armstrong G, Governale L: Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care 26:1852-1855, 2003
4. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 35). Lancet 352:837-853, 1998
5. Schwabe U, Paffrath D, Eds.: Arzneiverordnungs-Report 2005. Berlin, Springer-Verlag, 2006
6. Melander A, Folino-Gallo P, Walley T, Schwabe U, Groop PH, Klaukka T, Vallano A, Laporte J-R, Gallego MR, Schiapa M, Røder M, Kampmann JP, De Swaef A, Åberg M, Mansson O: Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels. Diabetologia 49:2024-2029, 2006
7. Hauner H, Köster I, von Ferber L: Prevalence of diabetes mellitus in Germany 1998-2001: secondary data analysis of a health insurance sample of the AOK in Hesse/KV in Hesse [in German]. Dtsch Med Wochenschr 128:2632-2638, 2003
8. Rathmann W, Haastert B, Roseman JM, Gries FA, Giani G: Prescription drug use and costs among diabetic patients in primary health care practices in Germany. Diabetes Care 21:389-397, 1998
9. Dietlein G, Schröder-Bernhardi D: Use of Mediplus patient database in healthcare research. Int J Pharmacol Ther 40:130-133, 2002
10. Krobot KJ, Miller WC, Kaufman JS, Christensen DB, Preisser JS, Ibrahim MA: Quantifying delay in access to new medical treatment: an application of risk advancement period methodology. Epidemiology 15:202-207, 2004
11. Liebl A, Neiß A, Spannheimer A, Reitberger U, Wagner T, Görtz A: Costs of type 2 diabetes in Germany: results of the CODE-2 Study [in German]. Dtsch Med Wochenschr 126:585-589, 2001
12. Stock SAK, Redaelli M, Wendland G, Civello D, Lauterbach KW: Diabetes-prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany. Diabet Med 23:299-305, 2005
13. Köster I, von Ferber L, Ihle P, Schubert I, Hauner H: The cost burden of diabetes mellitus: the evidence from Germany: the CoDiM Study. Diabetologia 49:1498-1504, 2006
14. Rothenbacher D, Ruter G, Saam S, Brenner H: Management of patients with type 2 diabetes: results in 12 practices of general practitioners [in German]. Dtsch Med Wochenschr 127:1183-1187, 2002
15. Bodenheimer T: High and rising health care costs. Part 1: seeking an explanation. Ann Intern Med 142:847-854, 2005
16. Bodenheimer T: High and rising health care costs. Part 2: technologic innovation. Ann Intern Med 142:932-937, 2005
17. Walley T, Hughes D, Kendall H: Trends and influences on use of antidiabetic drugs in England, 1992-2003. Pharmacoepidemiol Drug Saf 14:769-773, 2005
18. Böhler S, Scharnagl H, Freisinger F, Stojakovic T, Glaesmer H, Klotsche J, Pieper L, Pittrow D, Kirch W, Schneider H: Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany. Atherosclerosis 190:397-407, 2007
19. Bischoff B, Silber S, Richartz BM, Pieper L, Klotsche J, Wittchen HU, DETECT Study Group: Inadequate medical treatment of patients with coronary artery disease by primary care physicians in Germany. Clin Res Cardiol 95:405-412, 2006
20. Goldberg LD: The cost of migraine and its treatment. Am J Manag Care 11:S62-S67, 2005
21. Deckers JG, Schellevis FG, Fleming DM: WHO diagnostic criteria as a validation tool for the diagnosis of diabetes mellitus: a study in five European countries. Eur J Gen Pract 12:108-113, 2006